Global Percutaneous Coronary Intervention Guidance Devices Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Percutaneous Coronary Intervention Guidance Devices Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the percutaneous coronary intervention guidance devices market was valued at USD 2.10 billion in 2025 and is projected to reach USD 4.40 billion by 2033, growing at a CAGR of 9.70% from 2026 to 2033.
• The market is experiencing steady growth driven by the rising prevalence of coronary artery disease (CAD), increasing adoption of minimally invasive cardiovascular procedures, and continuous technological advancements in intravascular imaging and physiological assessment technologies.
• The increasing burden of aging populations and cardiovascular diseases worldwide, combined with growing clinical evidence supporting image-guided and physiology-guided PCI, is encouraging hospitals and cardiac catheterization laboratories to adopt advanced guidance devices. In addition, ongoing innovations in real-time imaging, AI-assisted procedural planning, and precision-guided coronary interventions are improving procedural accuracy, reducing complications, and enhancing long-term patient outcomes, thereby accelerating market growth.

Market Size & Forecast

• Global Market Value (2025): USD 2.10 Billion
• Expected Market Value (2033): USD 4.40 Billion
• Forecast CAGR (2026–2033): 9.70%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

What are the Major Takeaways of the Percutaneous Coronary Intervention Guidance Devices Market?

• North America dominated the percutaneous coronary intervention guidance devices market with the largest revenue share of 38.7% in 2025, supported by advanced cardiovascular care infrastructure, favorable reimbursement policies, and widespread adoption of intravascular imaging technologies.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 9.3% from 2026 to 2033, fueled by the rising burden of cardiovascular diseases, expanding healthcare infrastructure, increasing healthcare expenditure, and growing adoption of advanced PCI guidance technologies across China, India, and Japan.
• The guidewires segment led the market with a 39.8% share in 2025, driven by their indispensable role in virtually every percutaneous coronary intervention procedure.
• Balloon catheters are the fastest-growing device type, projected to register a CAGR of 9.2%, reflecting the surge in adoption of specialty balloons such as drug-coated balloons, scoring balloons, and cutting balloons for complex coronary lesions.
• The coronary artery disease (CAD) segment dominated the application category with a 52.3% revenue share in 2025, led by the high global prevalence of atherosclerotic coronary artery disease and the increasing number of PCI procedures performed annually
• Metal accounted for 84.6% of the market share in 2025, preferred by its superior mechanical strength, flexibility, durability, and proven clinical performance in coronary intervention devices.
• The needle clipping mechanism segment is the fastest-growing safety mechanism category, with a CAGR of 8.6%, driven by increasing demand for cost-effective sharps safety solutions across hospitals and ambulatory care settings.

Report Scope and Percutaneous Coronary Intervention Guidance Devices Market Segmentation

What is the Key Trend in the Percutaneous Coronary Intervention Guidance Devices Market?

• Image-guided and physiology-guided percutaneous coronary intervention (PCI) is increasingly becoming the standard of care, enabling accurate lesion assessment, optimized stent deployment, and improved long-term clinical outcomes while reducing procedural complications.
• For instance, in August 2024, the European Society of Cardiology (ESC) updated its Chronic Coronary Syndromes Guidelines, strengthening recommendations for the use of intracoronary imaging and physiological assessment to optimize PCI outcomes.
• Real-time intravascular imaging enables physicians to evaluate plaque morphology, vessel dimensions, and stent expansion with greater procedural precision.
• Hospitals and cardiac catheterization laboratories are increasingly adopting IVUS- and OCT-guided PCI to provide standardized, evidence-based coronary interventions for complex lesions.
• For instance, in September 2024, Philips announced that the 2024 European Society of Cardiology (ESC) Guidelines granted a Class IA recommendation for intravascular ultrasound (IVUS) in anatomically complex PCI and maintained Class IA recommendations for instantaneous wave-free ratio (iFR), reinforcing the growing adoption of image-guided and physiology-guided PCI.
• As healthcare providers continue to prioritize precision-guided coronary interventions and evidence-based treatment strategies, the adoption of advanced PCI guidance devices is expected to accelerate, reinforcing intracoronary imaging and physiological assessment as core components of modern interventional cardiology.

What are the Key Drivers of the Percutaneous Coronary Intervention Guidance Devices Market?

• The rising prevalence of coronary artery disease (CAD) and the growing preference for minimally invasive coronary revascularization procedures have significantly increased demand for advanced PCI guidance devices capable of improving procedural precision and long-term clinical outcomes.
• For instance, in October 2023, Abbott launched its AI-powered Ultreon 1.0 Software in India, combining Optical Coherence Tomography (OCT) with artificial intelligence to help physicians optimize stent sizing, deployment, and expansion during percutaneous coronary intervention (PCI), improving procedural precision and patient outcomes
• Hospitals, cardiac centers, and healthcare providers are increasingly integrating IVUS, OCT, and physiological assessment technologies into routine PCI workflows to improve stent optimization and reduce adverse cardiovascular events.
• For instance, in May 2024, Abbott launched the next-generation XIENCE Sierra Everolimus Drug Eluting Coronary Stent System in India, designed to enhance precision and deliverability in complex percutaneous coronary intervention (PCI) procedures, reinforcing the growing demand for advanced coronary intervention technologies.
• With cardiovascular disease continuing to rise globally and clinical guidelines increasingly recommending imaging-guided PCI, advanced guidance devices will remain essential for improving procedural safety and treatment outcomes.

Which Factors are Challenging the Growth of the Next Generation Tobacco Products Market?

• Advanced PCI guidance devices require significant upfront investment due to the integration of high-resolution imaging consoles, disposable catheters, pressure wires, and sophisticated physiological assessment technologies.
• These high costs limit adoption among smaller hospitals, ambulatory cardiac centers, and healthcare providers in emerging economies with constrained healthcare budgets.
• For instance, in January 2024, the Society for Cardiovascular Angiography & Interventions (SCAI) published its Expert Consensus Statement on the Management of Calcified Coronary Lesions, highlighting that complex PCI often requires specialized intracoronary imaging, dedicated equipment, and experienced operators, which increases procedural complexity and limits broader adoption.
• The requirement for specialized physician training and additional procedural time further increases operational costs and limits routine implementation across many healthcare settings.
• For instance, in August 2024, the SCAI Coronary Think Tank Proceedings reported that reimbursement challenges, operator training, performance feedback, and workflow integration remain key barriers limiting the broader adoption of intravascular coronary imaging during PCI despite growing clinical evidence supporting its use.
• The high capital investment, reimbursement challenges, and training requirements associated with advanced PCI guidance systems continue to restrict adoption, particularly in developing healthcare markets, limiting the broader utilization of image-guided coronary interventions despite strong clinical evidence supporting their benefits.

How is the Percutaneous Coronary Intervention Guidance Devices Market Segmented?

The percutaneous coronary intervention guidance devices market is segmented on the basis of device type, application, material type, safety mechanism, and end user.

• By Device Type

On the basis of device type, the percutaneous coronary intervention guidance devices market is segmented into percutaneous sheath introducers, guide catheters, guidewires, and balloon catheters. The guidewires segment dominated the market with 39.8% share in 2025, owing to their indispensable role in virtually every percutaneous coronary intervention procedure. Guidewires provide the primary pathway for delivering balloons, stents, imaging catheters, and other interventional devices across coronary lesions. Continuous advancements in steerability, torque control, hydrophilic coatings, and lesion-crossing capabilities have significantly improved procedural success rates. They are extensively used in both routine and complex interventions, including chronic total occlusions (CTOs) and bifurcation lesions. The increasing global volume of PCI procedures and the availability of specialized guidewires for different lesion characteristics continue to strengthen segment dominance. Their universal use across coronary interventions makes guidewires the largest revenue-generating device category.

The balloon catheters segment is projected to register the fastest growth at a CAGR of 9.2% from 2026 to 2033, driven by increasing adoption of specialty balloons such as drug-coated balloons, scoring balloons, and cutting balloons for complex coronary lesions. These devices improve lesion preparation, optimize stent expansion, and reduce restenosis in selected patient populations. Continuous technological advancements in balloon materials and deliverability are enhancing procedural outcomes. Rising preference for minimally invasive coronary interventions and increasing treatment of calcified lesions are further supporting demand. Growing clinical evidence for drug-coated balloon therapy in specific indications is also accelerating market expansion. The expanding use of advanced balloon technologies in complex PCI procedures is expected to sustain rapid growth.

• By Application

On the basis of application, the market is segmented into coronary artery disease (CAD), acute coronary syndrome (ACS), myocardial infarction, and others. The coronary artery disease (CAD) segment dominated the market with 52.3% share in 2025, driven by the high global prevalence of atherosclerotic coronary artery disease and the increasing number of PCI procedures performed annually. CAD remains the leading indication for coronary angioplasty and stent implantation worldwide. Growing adoption of intravascular imaging and physiological assessment technologies has significantly improved treatment precision in CAD patients. Increasing aging populations and lifestyle-related cardiovascular risk factors continue to expand the patient pool. Continuous improvements in PCI techniques and guideline-supported use of imaging-guided interventions further strengthen segment growth. The widespread burden of CAD ensures its continued market leadership.

The acute coronary syndrome (ACS) segment is projected to witness the fastest growth at a CAGR of 9.0% from 2026 to 2033, driven by increasing emergency PCI procedures and rising awareness regarding rapid coronary revascularization. Hospitals are increasingly adopting advanced PCI guidance devices to improve procedural outcomes in high-risk ACS patients. The growing availability of specialized cardiac centers and catheterization laboratories is further supporting market expansion. Technological innovations enabling faster lesion assessment and real-time procedural guidance are improving treatment efficiency. Expanding healthcare infrastructure in emerging economies is also increasing access to advanced ACS management. These factors are expected to accelerate growth throughout the forecast period.

• By Material Type

On the basis of material type, the market is segmented into metal and biodegradable polymers. The metal segment dominated the market with 84.6% share in 2025, owing to its superior mechanical strength, flexibility, durability, and proven clinical performance in coronary intervention devices. Stainless steel, nitinol, and cobalt-chromium alloys are extensively used in guidewires, guide catheters, and sheath introducers. These materials provide excellent torque transmission, pushability, and procedural reliability during complex coronary interventions. Long-established manufacturing processes and extensive physician familiarity continue to support widespread adoption. Their compatibility with advanced device designs further enhances clinical performance. The consistent demand for durable interventional devices maintains the dominance of the metal segment.

The biodegradable polymers segment is projected to register the fastest growth at a CAGR of 10.4% from 2026 to 2033, driven by increasing research into next-generation cardiovascular devices with improved biocompatibility. These materials are being incorporated into advanced balloon technologies and other coronary intervention products to reduce long-term inflammatory responses. Continuous innovation in biomaterials is supporting broader clinical applications. Growing emphasis on improving vascular healing and reducing device-related complications is encouraging product development. Expanding investment in biodegradable medical technologies is further supporting adoption. Ongoing technological advancements are expected to accelerate segment growth.

• By Safety Mechanism

On the basis of safety mechanism, the market is segmented into needle clipping mechanism and needle shielding mechanism. The needle shielding mechanism segment dominated the market with 61.5% share in 2025, owing to its ability to reduce accidental needlestick injuries and improve healthcare worker safety during vascular access procedures. Automatic shielding systems provide immediate protection after device deployment, minimizing occupational exposure to bloodborne pathogens. Hospitals increasingly prefer these systems to comply with workplace safety regulations and infection prevention protocols. Growing awareness regarding clinician safety is supporting higher adoption rates. Continuous innovation in passive safety technologies is further improving device usability. These advantages continue to strengthen the segment's leading market position.

The needle clipping mechanism segment is expected to witness the fastest growth at a CAGR of 8.6% from 2026 to 2033, driven by increasing demand for cost-effective sharps safety solutions across hospitals and ambulatory care settings. These systems provide secure needle containment following vascular access procedures while reducing disposal-related injuries. Expanding regulatory emphasis on healthcare worker protection is encouraging wider implementation. Manufacturers are developing simplified clipping technologies that improve workflow efficiency without increasing procedural complexity. Growing healthcare infrastructure in developing countries is also supporting adoption. These factors are expected to contribute to sustained segment growth.

• By End User

On the basis of end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs), cardiac catheterization laboratories, and others. The hospitals segment dominated the market with 67.2% share in 2025, driven by the high volume of PCI procedures performed in tertiary care centers and multispecialty hospitals. Hospitals possess comprehensive catheterization laboratory infrastructure, advanced imaging systems, and experienced interventional cardiologists required for complex coronary interventions. The availability of emergency cardiac care and multidisciplinary treatment teams further supports higher procedural volumes. Increasing investments in cardiovascular infrastructure are strengthening hospital-based adoption of advanced PCI guidance technologies. Favorable reimbursement policies in developed markets also contribute to sustained utilization. These factors continue to position hospitals as the leading end-user segment.

The cardiac catheterization laboratories segment is projected to register the fastest growth at a CAGR of 9.5% from 2026 to 2033, driven by increasing establishment of dedicated cardiovascular intervention centers and growing demand for minimally invasive coronary procedures. These specialized laboratories offer advanced imaging technologies and optimized procedural workflows for high-volume PCI cases. Rising investments in hybrid cath labs and digital imaging platforms are improving operational efficiency. Growing adoption of image-guided PCI and physiology-based assessment technologies is further accelerating demand. Expanding cardiovascular disease burden and increasing procedural specialization are supporting continued market growth. The trend toward dedicated interventional facilities is expected to sustain rapid expansion of this segment.

Which Region Holds the Largest Share of the Percutaneous Coronary Intervention Guidance Devices Market?

• North America dominated the percutaneous coronary intervention guidance devices market with the largest revenue share of 38.7% in 2025, supported by advanced cardiovascular care infrastructure, favorable reimbursement policies, and widespread adoption of intravascular imaging technologies.
• The region also benefits from the widespread adoption of intravascular imaging and physiological assessment technologies, increasing prevalence of coronary artery disease, growing preference for minimally invasive coronary interventions, and continuous investments in cardiac catheterization laboratories and interventional cardiology innovation. These factors continue to strengthen North America's leadership position in the global market.

U.S. Percutaneous Coronary Intervention Guidance Devices Market Insight

The U.S. percutaneous coronary intervention guidance devices market is witnessing strong growth due to rising prevalence of coronary artery disease, increasing adoption of intravascular imaging technologies, and continuous investments in advanced interventional cardiology infrastructure. The country's well-established healthcare system, favorable reimbursement framework, and strong presence of leading cardiovascular device manufacturers are driving demand across hospitals and cardiac catheterization laboratories. In addition, growing physician preference for IVUS-, OCT-, and physiology-guided PCI, supported by robust clinical evidence and updated treatment guidelines, is accelerating the adoption of advanced PCI guidance devices. In September 2024, the 2024 ESC Guidelines granted Class I, Level A recommendations for IVUS in anatomically complex PCI and maintained Class I, Level A recommendations for iFR, strengthening global adoption of imaging-guided PCI technologies.

Asia-Pacific Percutaneous Coronary Intervention Guidance Devices Market Insight

The Asia-Pacific percutaneous coronary intervention guidance devices market is expected to witness rapid growth, driven by increasing cardiovascular disease prevalence, expanding healthcare infrastructure, and rising investments in advanced cardiac care across China, India, Japan, and South Korea. Growing awareness regarding minimally invasive coronary interventions, increasing availability of catheterization laboratories, and rising healthcare expenditure are supporting regional market expansion. In addition, expanding adoption of intravascular imaging technologies and increasing government initiatives to improve cardiovascular care are accelerating market growth throughout the region. In October 2023, Abbott launched its AI-powered Ultreon 1.0 Software in India, enabling AI-assisted OCT imaging for optimized PCI planning and stent deployment.

Japan Percutaneous Coronary Intervention Guidance Devices Market Insight

The Japan percutaneous coronary intervention guidance devices market is witnessing consistent growth due to increasing adoption of image-guided coronary interventions, strong cardiovascular research capabilities, and widespread availability of advanced catheterization laboratories. Hospitals and cardiovascular specialists are increasingly utilizing IVUS, OCT, and physiological assessment technologies to improve procedural precision and optimize patient outcomes. Moreover, continuous technological innovation and the country's aging population with a high burden of cardiovascular disease are further contributing to market growth. Japan remains one of the world's leading adopters of IVUS-guided PCI, and the ULTIMATE trial, led by Japanese and Asian investigators, demonstrated superior long-term outcomes with IVUS-guided PCI compared with angiography-guided PCI.

China Percutaneous Coronary Intervention Guidance Devices Market Insight

The China percutaneous coronary intervention guidance devices market is growing rapidly, driven by increasing incidence of coronary artery disease, expanding healthcare infrastructure, and rising government investments in cardiovascular care. Growing adoption of intravascular imaging technologies, increasing PCI procedure volumes, and rapid expansion of tertiary hospitals are significantly boosting market demand. In addition, continuous investments in domestic medical device innovation and growing physician awareness regarding evidence-based PCI are positioning China as one of the fastest-growing markets for PCI guidance devices. The Chinese Society of Cardiology continued promoting standardized image-guided PCI through updated clinical education and training initiatives aligned with international recommendations.

U.K. Percutaneous Coronary Intervention Guidance Devices Market Insight

The U.K. percutaneous coronary intervention guidance devices market is experiencing steady growth, supported by increasing adoption of intravascular imaging technologies, expanding minimally invasive cardiovascular procedures, and strong implementation of evidence-based treatment guidelines. Rising investments in catheterization laboratory modernization and growing demand for precision-guided coronary interventions are contributing to market growth. Furthermore, increasing integration of AI-assisted imaging technologies and digital cardiovascular platforms is improving procedural efficiency and patient outcomes across the country. In August 2024, the European Society of Cardiology (ESC) updated its Chronic Coronary Syndromes Guidelines, strengthening recommendations for intracoronary imaging and physiological assessment during PCI, supporting adoption across European healthcare systems, including the U.K.

Germany Percutaneous Coronary Intervention Guidance Devices Market Insight

The Germany percutaneous coronary intervention guidance devices market is expanding steadily due to the country's advanced cardiovascular healthcare infrastructure, strong interventional cardiology expertise, and increasing utilization of image-guided PCI technologies. Hospitals and cardiac centers are increasingly adopting IVUS, OCT, and coronary physiology assessment to optimize complex coronary interventions and improve long-term clinical outcomes. Continuous investments in digital health technologies and strong participation in multinational cardiovascular clinical research are further driving market growth in Germany. The European Society of Cardiology (ESC) issued updated guidelines providing stronger recommendations for intracoronary imaging and physiological assessment, encouraging broader implementation of image-guided PCI across Germany and other European countries.

Which are the Top Companies in Percutaneous Coronary Intervention Guidance Devices Market?

The percutaneous coronary intervention guidance devices industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Terumo Corporation (Japan)
• Asahi Intecc Co., Ltd. (Japan)
• Teleflex Incorporated (U.S.)
• Merit Medical Systems, Inc. (U.S.)
• Cardinal Health (U.S.)
• B. Braun SE (Germany)
• Nipro Corporation (Japan)
• BIOTRONIK SE & Co. KG (Germany)
• Kaneka Corporation (Japan)
• OrbusNeich Medical Group Holdings Limited (Hong Kong)
• iVascular S.L.U. (Spain)
• BrosMed Medical Co., Ltd. (China)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• SMT (India)
• HEXACATH (France)
• Balton. (Poland)
• QT Vascular Ltd. (Singapore)

What are Latest Developments in Percutaneous Coronary Intervention Guidance Devices Market?

• In December 2025, Philips announced the expanded commercial availability of LumiGuide, the world's first real-time AI-enabled light-based 3D device guidance technology integrated with the Azurion image-guided therapy platform. The solution enhances minimally invasive image-guided cardiovascular and vascular procedures by enabling real-time navigation while reducing reliance on X-ray imaging and contrast agents.
• In December 2025, Philips announced an agreement to acquire SpectraWAVE Inc. to strengthen its coronary intravascular imaging and physiological assessment portfolio. The acquisition adds SpectraWAVE's HyperVue Imaging System and AI-enabled X1 -FFR technology to Philips' PCI guidance portfolio, expanding AI-assisted coronary imaging and physiology solutions for image-guided interventions.
• In August 2023, Abbott presented the ILUMIEN IV OPTIMAL PCI study demonstrating the benefits of its Optical Coherence Tomography (OCT) imaging platform for PCI guidance. The study showed OCT-guided PCI improved stent expansion and reduced stent thrombosis compared with angiography-guided PCI, reinforcing adoption of advanced intracoronary imaging technologies.
• In April 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI), expanding its vascular intervention portfolio with CSI's orbital atherectomy technology used to prepare calcified coronary and peripheral arteries before angioplasty and stent implantation. The acquisition strengthens Abbott's capabilities in complex coronary interventions by complementing its existing intravascular imaging and PCI product portfolio, enabling physicians to better treat challenging calcified lesions.
• In March 2021, Philips, the American College of Cardiology (ACC), and MedAxiom announced a strategic collaboration to improve cardiovascular care delivery through clinical, operational, and financial performance initiatives. The partnership focuses on advancing evidence-based cardiovascular care and accelerating adoption of innovative image-guided technologies across catheterization laboratories.

SKU-76570